Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis, Astellas Intend To Disprove Eczema Treatments’ Cancer Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis and Astellas aim to use ongoing studies to convince FDA to remove a requirement for a "black box" warning of potential cancer risk in labeling for their topical calcineurin inhibitors

You may also be interested in...



FDA Approves Boxed Warning On Cancer Risk For Elidel And Protopic

The agency finalized the addition of the boxed warnings and revised indications for the eczema therapies' labels one year after a similar recommendation by an FDA advisory committee.

FDA Approves Boxed Warning On Cancer Risk For Elidel And Protopic

The agency finalized the addition of the boxed warnings and revised indications for the eczema therapies' labels one year after a similar recommendation by an FDA advisory committee.

Novartis' Elidel, Fujisawa's Protopic To Add "Black Box" On Cancer Risk

Novartis expects labeling negotiations will begin within the next few weeks and says a "black box" is unjustified. A medication guide will also be required for the eczema treatments, FDA says.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel